#151339

Anti-SIGLEC2 [4KB128]

Cat. #151339

Anti-SIGLEC2 [4KB128]

Cat. #: 151339

Sub-type: Primary antibody

Unit size: 100 ug

Availability: 3-4 weeks

Target: Sialic acid binding Ig-like lectin 2 (SIGLEC2, CD22, BL-CAM)

Class: Monoclonal

Application: FACS

Reactivity: Human

Host: Mouse

£300.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Karen Pulford

Institute: University of Oxford

Tool Details
Target Details
Applications
Handling
References

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Name: Anti-SIGLEC2 [4KB128]
  • Research fields: Cancer;Immunology;Stem cell biology
  • Clone: 4KB128
  • Tool sub type: Primary antibody
  • Class: Monoclonal
  • Conjugation: Unconjugated
  • Reactivity: Human
  • Host: Mouse
  • Application: FACS
  • Description: SIGLEC-2 is first expressed in the cytomplasm of pre- and pro- B cells. SIGLEC-2 is broadly expressed in normal and neoplastic B cells and absent from other leucocytes and tissues. SIGLEC-2 is a member of the immunoglobulin superfamily and serves as an adhesion receptor for sialic acid-bearing ligands expressed on erythrocytes and all leukocyte classes. It also associates with tyrosine kinases and play a role in signal transduction and B-cell activation. SIGLEC-2 is strongly expressed in hairy cell leukaemias.
  • Immunogen: B cell lymphoma cells
  • Isotype: IgG1 kappa
  • Myeloma used: P3/NS1/1-Ag4.1

Target Details

  • Target: Sialic acid binding Ig-like lectin 2 (SIGLEC2, CD22, BL-CAM)
  • Target background: SIGLEC-2 is first expressed in the cytomplasm of pre- and pro- B cells. SIGLEC-2 is broadly expressed in normal and neoplastic B cells and absent from other leucocytes and tissues. SIGLEC-2 is a member of the immunoglobulin superfamily and serves as an adhesion receptor for sialic acid-bearing ligands expressed on erythrocytes and all leukocyte classes. It also associates with tyrosine kinases and play a role in signal transduction and B-cell activation. SIGLEC-2 is strongly expressed in hairy cell leukaemias.

Applications

  • Application: FACS

Handling

  • Format: Liquid
  • Concentration: 0.9-1.1 mg/ml
  • Unit size: 100 ug
  • Storage buffer: PBS with 0.02% azide
  • Storage conditions: -15° C to -25° C
  • Shipping conditions: Dry ice

References

  • Law et al. 1994. Immunol Today. 15(9):442-9. PMID: 7945784.
  • Regulation of lymphocyte activation by the cell-surface molecule CD22.
  • Mason et al. 1987. Blood. 69(3):836-40. PMID: 3101766.
  • Value of monoclonal anti-CD22 (p135) antibodies for the detection of normal and neoplastic B lymphoid cells.
  • Campana et al. 1985. J Immunol. 134(3):1524-30. PMID: 3918103.
  • Human B cell development. I. Phenotypic differences of B lymphocytes in the bone marrow and peripheral lymphoid tissue.

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.